Impact Factor 4.137 | CiteScore 4.28
More on impact ›
This section is focused on the discovery of molecular targets in cancer, targetable molecules in cancer signaling pathways, and their application in drug development and therapeutics. One of the greatest challenges after the discovery of cancer specific targets is to decipher the complexity of the targetable protein function and to develop innovative target-only drugs which selectively fight cancer but not normal cells. On the other hand, effective drugs can have multiple molecular targets and impact on several key pathways or hallmarks of cancer.
Given the explosion of new information in molecular oncogenesis and the rapidly growing momentum of target-specific therapies, our section highlights new discoveries, approaches, and technical developments in cancer molecular target identification, drug development as well as discovery-driven cancer translational research.
With this in mind, we aim to translate the fundamental knowledge of oncogenes and tumor suppressor genes into prototypes for cancer therapy, including targets previously thought as undruggable. For effective translation, biomarkers of drug action, and strategies for validation and understanding the clinical basis for drug efficacy and resistance have emerged as fundamentally important areas.
Priority will be given to preclinical and translational evaluations of novel targets and functioning of the target specific therapeutics. Submissions should present significant new information on the mechanisms of targetable molecules in cancer development and metastasis and target-specific therapies. Mechanistic studies that use innovative molecular profiling as well as single cell technologies, 3-D cultures, organoids and mouse models are welcomed. We welcome innovative early phase clinical trials and proof-of-concept studies that build upon basic knowledge of drug targets and biomarkers.
We are also interested in drug actions encompassing the following areas: cancer targetable genes, innovative models of target-specific therapies, drug sensitivity and resistance with attention to the tumor microenvironment and host, cancer stem cells, immune mechanisms, pharmacokinetics and pharmacodynamics, structure-activity relationships, gene therapy, and early-stage development of promising new target-specific compounds or their analogues.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
Cancer Molecular Targets and Therapeutics welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Cancer Molecular Targets and Therapeutics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cancer Molecular Targets and Therapeutics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com